Tenaya CEO sells 22K shares at about $0.71

Tenaya Therapeutics, Inc. director and Chief Executive Officer Ali Faraz reported selling an aggregate 22,232 shares of common stock on 2026-08-17 in four open-market transactions at weighted average prices of about $0.71 per share.

Rhea-AI Filing Summary

Tenaya Therapeutics, Inc. director and Chief Executive Officer Ali Faraz reported selling an aggregate 22,232 shares of common stock on 2026-08-17 in four open-market transactions at weighted average prices of about $0.71 per share. Footnotes state each sale covered tax withholding obligations arising from the vesting of restricted stock units granted on February 15, 2023, February 23, 2024, February 6, 2025, and February 3, 2026, respectively. Additional disclosure notes future issuance of 305,956, 295,331, 281,894, and 262,069 shares upon vesting of these restricted stock units.

Insider Trade Summary

Net Seller: 22,232 shares

Net Sell 4 txns

Insider Ali Faraz

Role Chief Executive Officer

Sold 22,232 shs ($16K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2, F3	5,837	$0.7097	$4K
Sale	Common Stock F4, F2, F5	3,969	$0.7098	$3K
Sale	Common Stock F6, F2, F7	5,020	$0.7097	$4K
Sale	Common Stock F8, F2, F9	7,406	$0.7097	$5K

Holdings After Transaction: Common Stock — 417,782 shares (Direct)

Footnotes (9)

1. F1. Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023.
2. F2. Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $.6820 to $.7253. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
3. F3. Includes 305,956 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
4. F4. Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 23, 2024.
5. F5. Includes 295,331 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
6. F6. Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 6, 2025.
7. F7. Includes 281,894 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
8. F8. Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 3, 2026.
9. F9. Includes 262,069 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

Key Figures

Total shares sold: 22,232 shares Block sale 1: 5,837 shares at $0.7097 per share Block sale 2: 3,969 shares at $0.7098 per share +5 more

8 metrics

Total shares sold 22,232 shares Aggregate common stock sales by Ali Faraz on 2026-08-17

Block sale 1 5,837 shares at $0.7097 per share First sale of common stock on 2026-08-17

Block sale 2 3,969 shares at $0.7098 per share Second sale of common stock on 2026-08-17

Block sale 3 5,020 shares at $0.7097 per share Third sale of common stock on 2026-08-17

Block sale 4 7,406 shares at $0.7097 per share Fourth sale of common stock on 2026-08-17

Trade price range $0.6820 to $0.7253 per share Footnote range for multiple sale transactions

Future RSU-related shares (2023 grant) 305,956 shares Shares to be issued upon vesting of RSUs awarded February 15, 2023

Future RSU-related shares (2026 grant) 262,069 shares Shares to be issued upon vesting of RSUs awarded February 3, 2026

Key Terms

restricted stock units, tax withholding obligations, weighted average sales price

3 terms

restricted stock units financial

"in connection with the vesting of restricted stock units awarded on February 15, 2023"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"Shares sold to cover tax withholding obligations in connection with the vesting"

weighted average sales price financial

"Represents the weighted average sales price. The shares were sold in multiple"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Tenaya Therapeutics (TNYA) CEO Ali Faraz report on this Form 4?

Ali Faraz reported selling 22,232 shares of Tenaya Therapeutics common stock on 2026-08-17 in four open-market transactions. The filing notes these sales were linked to tax withholding obligations from vesting restricted stock units granted across four prior grant dates.

At what prices were the Tenaya Therapeutics (TNYA) shares sold by CEO Ali Faraz?

The reported weighted average sale prices were around $0.71 per share, with entries of $0.7097 and $0.7098. A footnote explains that individual trades occurred in a price range from $0.6820 to $0.7253 per share across multiple transactions.

How many Tenaya Therapeutics (TNYA) shares did Ali Faraz sell in each transaction?

On 2026-08-17, Ali Faraz reported four sales of 5,837, 3,969, 5,020, and 7,406 shares of common stock. Together these transactions totaled 22,232 shares, all reported as direct ownership sales in non-derivative securities.

Why did Tenaya Therapeutics (TNYA) CEO Ali Faraz sell shares according to this Form 4?

Each sale is described as shares sold to cover tax withholding obligations triggered by the vesting of specific restricted stock unit awards. The footnotes tie each transaction to RSU grants made in 2023, 2024, 2025, and 2026, respectively, upon their vesting.

What restricted stock unit (RSU) positions for Tenaya Therapeutics (TNYA) does Ali Faraz still have related to these transactions?

Footnotes state that, upon vesting, RSUs will result in issuances of 305,956, 295,331, 281,894, and 262,069 shares of common stock. These amounts relate to the RSU awards associated with the tax-withholding sales reported in this Form 4.

Were the Tenaya Therapeutics (TNYA) insider sales by Ali Faraz made under a Rule 10b5-1 trading plan?

The Form 4 indicates the Rule 10b5-1 checkbox is not affirmatively marked, and no footnote describes the transactions as pursuant to a trading plan. The filing instead emphasizes the sales’ purpose as satisfying tax withholding obligations from RSU vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/17/2026 - 08:50 PM Accepted by SEC EDGAR 08/17/2026 - 08:50 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ali Faraz

(Last) (First) (Middle)

C/O TENAYA THERAPEUTICS, INC.

171 OYSTER POINT BLVD., 5TH FLOOR

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tenaya Therapeutics, Inc. [ TNYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/17/2026		S(1)		5,837	D	$0.7097(2)	434,177(3)	D
Common Stock	08/17/2026		S(4)		3,969	D	$0.7098(2)	430,208(5)	D
Common Stock	08/17/2026		S(6)		5,020	D	$0.7097(2)	425,188(7)	D
Common Stock	08/17/2026		S(8)		7,406	D	$0.7097(2)	417,782(9)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023.

2. Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $.6820 to $.7253. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

3. Includes 305,956 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

4. Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 23, 2024.

5. Includes 295,331 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

6. Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 6, 2025.

7. Includes 281,894 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

8. Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 3, 2026.

9. Includes 262,069 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

	/s/ Jennifer Drimmer Rokovich, Attorney-in-Fact	08/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)